RNA-guided nucleases and active fragments and variants thereof and methods of use
Compositions and methods for binding to a target sequence of interest are provided. The compositions find use in cleaving or modifying a target sequence of interest, visualization of a target sequence of interest, and modifying the expression of a sequence of interest. Compositions comprise RNA-guided nuclease polypeptides, CRISPR RNAs, trans-activating CRISPR RNAs, guide RNAs, and nucleic acid molecules encoding the same. Vectors and host cells comprising the nucleic acid molecules are also provided. Further provided are CRISPR systems for binding a target sequence of interest, wherein the CRISPR system comprises an RNA-guided nuclease polypeptide and one or more guide RNAs.
1. A fusion polypeptide comprising:
(A) an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36; and
(B) a heterologous polypeptide.
2. The fusion polypeptide of claim 1 , wherein the heterologous polypeptide comprises a cell penetrating domain or an effector domain.
3. The fusion polypeptide of claim 2 , wherein the effector domain comprises a cleavage domain, a deaminase domain, or an expression modulator domain.
4. The fusion polypeptide of claim 1 , wherein the RGN polypeptide of (i) or (ii) is nuclease dead or functions as a nickase.
5. The fusion polypeptide of claim 1 , wherein the heterologous polypeptide comprises a base-editing polypeptide.
6. The fusion polypeptide of claim 5 , wherein the base-editing polypeptide is a deaminase.
7. The fusion polypeptide of claim 1 , wherein the fusion polypeptide further comprises one or more nuclear localization signals.
8. A cell comprising the fusion polypeptide of claim 1 .
9. The cell of claim 8 , wherein the cell is a eukaryotic cell.
10. A nucleic acid molecule comprising a polynucleotide encoding the fusion polypeptide of claim 1 .
11. A vector comprising the nucleic acid molecule of claim 10 .
12. An RNA polynucleotide comprising a nucleotide sequence encoding the fusion polypeptide of claim 1 .
13. The RNA polynucleotide of claim 12 , wherein the heterologous polypeptide comprises a base-editing polypeptide.
14. The RNA polynucleotide of claim 12 , wherein the RNA polynucleotide is an mRNA.
15. An RNA polynucleotide comprising:
(A) a nucleotide sequence encoding an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identify to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
and
(B) a heterologous 5′ or 3′ regulatory sequence.
16. A method for making an RGN polypeptide comprising:
introducing into a cell a heterologous nucleic acid molecule comprising a nucleotide sequence encoding an RNA-guided nuclease (RGN) polypeptide comprising an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identify to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
and
culturing the cell under conditions in which the RGN polypeptide is expressed.
17. A method for binding a target DNA sequence comprising delivering an RGN polypeptide comprising an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
to the target DNA sequence or a cell comprising the target DNA sequence, wherein said RGN polypeptide is capable of forming a RGN ribonucleotide complex with one or more guide RNAs capable of hybridizing to the target DNA sequence.
18. A method for producing a genetically modified cell with a correction in a causal mutation for a genetically inherited disease, the method comprising introducing into a cell:
a) an RNA-guided nuclease (RGN) polypeptide, wherein the RGN polypeptide comprises an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
or a polynucleotide encoding the RGN polypeptide operably linked to a promoter; and
b) a guide RNA (gRNA), wherein the gRNA comprises a CRISPR repeat comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NOs: 2, 12, 20, 28, 37, 46, or 55, or a polynucleotide encoding the gRNA operably linked to a promoter,
wherein the RGN polypeptide and the gRNA target to and modify a genomic sequence in the cell comprising the causal mutation, thereby producing a genetically modified cell with a correction in a causal mutation for a genetically inherited disease.
19. A method for producing a genetically modified cell with a deletion in a disease-causing genomic region of instability, the method comprising introducing into a cell:
a) an RNA-guided nuclease (RGN) polypeptide, wherein the RGN polypeptide comprises an amino acid sequence:
(i) having at least 95% sequence identity to any one of SEQ ID NOs: 11, 27, 45, or 54;
(ii) having at least 98% sequence identity to SEQ ID NOs: 1 or 19; or
(iii) set forth as SEQ ID NO: 36;
or a polynucleotide encoding the RGN polypeptide operably linked to a promoter; and
b) a first guide RNA (gRNA), wherein the first gRNA comprises a CRISPR repeat comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NOs: 2, 12, 20, 28, 37, 46, or 55, or a polynucleotide encoding the first gRNA operably linked to a promoter, and further wherein the first gRNA comprises a spacer that targets the 5′ flank of the genomic region of instability; and
c) a second gRNA, wherein the second gRNA comprises a CRISPR repeat comprising a nucleotide sequence having at least 95% sequence identity to SEQ ID NOs: 2, 12, 20, 28, 37, 46, or 55, or a polynucleotide encoding the second gRNA operably linked to a promoter, and further wherein the second gRNA comprises a spacer that targets the 3′ flank of the genomic region of instability;
wherein the RGN polypeptide and the first and second gRNAs target to and remove at least a portion of the genomic region of instability in the cell, thereby producing a genetically modified cell with a deletion in a disease-causing genomic region of instability.